The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

If you are wondering whether Pfizer's current share price reflects its underlying value, you are not alone. This article will ...

At J.P. Morgan 2026, Pfizer CEO Albert Bourla positioned the company as a post-COVID operator focused on disciplined ...

If you are wondering whether Pfizer's current share price offers value for what you are getting, this article breaks down the numbers so you can assess that for yourself. Pfizer's share price last ...

Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings ...

Pfizer PFE faces patent expirations amounting to more than one quarter of 2024 revenue by 2028, and the 2023 acquisition of oncology-focused biotech Seagen boosted the firm’s invested capital base, ...

Pfizer's stock has started to turn higher, but it is still down massively; is now the time to jump aboard?

Pfizer's been focusing on a hot area of healthcare recently: GLP-1 drugs.

Pfizer’s PFE third-quarter revenue fell 6%, as acquisition charges outweighed cost efficiencies and pushed adjusted diluted EPS down 18%. In the battle for Metsera’s obesity pipeline, Pfizer announced ...

In early January 2026, Pfizer Inc. and Boltz, PBC announced a collaboration to apply biomolecular AI foundation models to Pfizer’s historical R&D data, while a separate multi-year deal with ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.